Newsroom

CSRxP Statement on CMS Changes to Medicare Part B

CSRxP spokesman Will Holley released the following statement following CMS’ announcement of changes to prescription drug policies in Medicare Part B: “Today’s announcement from the Centers […]

Read more

New Report Demonstrates Big Pharma’s Abuses of the Patent System

CSRxP spokesman Will Holley released the following statement on the release of I-MAK’s report, “Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug […]

Read more

High Priced Drugs Lead to Banner Q2 Earnings for Big Pharma

CSRxP released the following statement following a week of strong Q2 earnings across the branded pharma sector: “While patients throughout the nation continue to suffer from […]

Read more

CSRxP on Lilly & Biogen Earnings

CSRxP released the following statement following the release of Eli Lilly and Biogen’s Q2 earnings today: “Out-of-control prescription drug prices are fueling profits for brand-name drug […]

Read more